In vivo efficacy and safety of artemether-lumefantrine and amodiaquine-artesunate for uncomplicated Plasmodium falciparum malaria in Mozambique, 2018

Abel Nhama, Lídia Nhamússua, Eusébio Macete, Quique Bassat, Crizolgo Salvador, Sónia Enosse, Baltazar Candrinho, Eva Carvalho, Arsénio Nhacolo, Arlindo Chidimatembue, Abuchahama Saifodine, Rose Zulliger, Naomi Lucchi, Samaly S Svigel, Leah F Moriarty, Eric S Halsey, Alfredo Mayor, Pedro Aide, Abel Nhama, Lídia Nhamússua, Eusébio Macete, Quique Bassat, Crizolgo Salvador, Sónia Enosse, Baltazar Candrinho, Eva Carvalho, Arsénio Nhacolo, Arlindo Chidimatembue, Abuchahama Saifodine, Rose Zulliger, Naomi Lucchi, Samaly S Svigel, Leah F Moriarty, Eric S Halsey, Alfredo Mayor, Pedro Aide

Abstract

Background: Artemisinin-based combination therapy (ACT) has been the recommended first-line treatment for uncomplicated malaria in Mozambique since 2006, with artemether-lumefantrine (AL) and amodiaquine-artesunate (AS-AQ) as the first choice. To assess efficacy of currently used ACT, an in vivo therapeutic efficacy study was conducted.

Methods: The study was conducted in four sentinel sites: Montepuez, Moatize, Mopeia and Massinga. Patients between 6 and 59 months old with uncomplicated Plasmodium falciparum malaria (2000-200,000 parasites/µl) were enrolled between February and September of 2018, assigned to either an AL or AS-AQ treatment arm, and monitored for 28 days. A Bayesian algorithm was applied to differentiate recrudescence from new infection using genotyping data of seven neutral microsatellites. Uncorrected and PCR-corrected efficacy results at day 28 were calculated.

Results: Totals of 368 and 273 patients were enrolled in the AL and AS-AQ arms, respectively. Of these, 9.5% (35/368) and 5.1% (14/273) were lost to follow-up in the AL and AS-AQ arms, respectively. There were 48 and 3 recurrent malaria infections (late clinical and late parasitological failures) in the AL and AS-AQ arms, respectively. The day 28 uncorrected efficacy was 85.6% (95% confidence interval (CI) 81.3-89.2%) for AL and 98.8% (95% CI 96.7-99.8%) for AS-AQ, whereas day 28 PCR-corrected efficacy was 97.9% (95% CI 95.6-99.2%) for AL and 99.6% (95% CI 97.9-100%) for AS-AQ. Molecular testing confirmed that 87.4% (42/48) and 33.3% (1/3) of participants with a recurrent malaria infection in the AL and AS-AQ arms were new infections; an expected finding in a high malaria transmission area. Adverse events were documented in less than 2% of participants for both drugs.

Conclusion: Both AL and AS-AQ have therapeutic efficacies well above the 90% WHO recommended threshold and remain well-tolerated in Mozambique. Routine monitoring of therapeutic efficacy should continue to ensure the treatments remain efficacious. Trial registration Clinicaltrials.gov: NCT04370977.

Keywords: Artemether–lumefantrine; Artesunate–amodiaquine; Children; Efficacy; Mozambique; Uncomplicated malaria.

Conflict of interest statement

Authors have no competing interests to declare.

© 2021. The Author(s).

Figures

Fig. 1
Fig. 1
Map of Mozambique with study sites
Fig. 2
Fig. 2
Trial profile
Fig. 3
Fig. 3
a Kaplan–Meier analysis of uncorrected efficacy according to the study arm. b Kaplan–Meier analysis of corrected efficacy according to the study arm
Fig. 4
Fig. 4
Kaplan–Meier curve showing time to negative parasitemia according to the study site, treatment arm and day of follow-up
Fig. 5
Fig. 5
Percentage of children with fever according to the follow-up day and study arm
Fig. 6
Fig. 6
Changes in mean haemoglobin according to the study arm

References

    1. WHO. World malaria report 2020: 20 years of global progress and challenges. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
    1. Instituto Nacional de Saúde (INS) and ICF. Inquérito Nacional sobre Indicadores de Malária em Moçambique 2018. Maputo, Moçambique. Rockville, USA. 2019.
    1. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of artemisinin-resistant malaria in Western Cambodia. N Engl J Med. 2008;359:2619–2620. doi: 10.1056/NEJMc0805011.
    1. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–467. doi: 10.1056/NEJMoa0808859.
    1. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med. 2009;361:540–541. doi: 10.1056/NEJMc0900231.
    1. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin–piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother. 2015;59:4719–4726. doi: 10.1128/AAC.00835-15.
    1. Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–55. doi: 10.1038/nature12876.
    1. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21:1120–1128. doi: 10.1016/S1473-3099(21)00142-0.
    1. Abacassamo F, Enosse S, Aponte JJ, Gómez-Olivé FX, Quintó L, Mabunda S, et al. Efficacy of chloroquine, amodiaquine, sulphadoxine–pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria. Trop Med Int Health. 2004;9:200–208. doi: 10.1046/j.1365-3156.2003.01182.x.
    1. Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Nabasumba C, et al. Lumefantrine for treating uncomplicated malaria in African children : a randomised, non-inferiority trial. PLoS ONE. 2009;4:e7871. doi: 10.1371/journal.pone.0007871.
    1. Abdulla S, Sagara I, Borrmann S, D’Alessandro U, Gonzalez R, Hamel M, et al. Efficacy and safety of artemether–lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet. 2008;372:1819–1827. doi: 10.1016/S0140-6736(08)61492-0.
    1. Nhama A, Bassat Q, Enosse S, Nhacolo A, Mutemba R, Carvalho E, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated falciparum malaria in children: a multisite, open-label, two-cohort, clinical trial in Mozambique. Malar J. 2014;13:309. doi: 10.1186/1475-2875-13-309.
    1. Salvador C, Rafael B, Matsinhe F, Candrinho B, Muthemba R, De Carvalho E, et al. Efficacy and safety of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015. Acta Trop. 2017;171:146–150. doi: 10.1016/j.actatropica.2017.03.032.
    1. Bassat Q, Gonzalez R, Machevo S, Nahum A, Lyimo J, Maiga H, et al. Similar efficacy and safety of artemether-lumefantrine (Coartem(R)) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malar J. 2011;10:369. doi: 10.1186/1475-2875-10-369.
    1. WHO. Methods for surveillance of antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2009. .
    1. WHO Severe falciparum malaria. Trans R Soc Trop Med Hyg. 2000;94 Suppl 1:S1–90.
    1. WHO. Guidelines for the treatment of malaria. 3rd edition. Geneva: World Health Organization; 2015. .
    1. MISAU/DNSP/PNCM. Normas de Tramento da malária em Moçambique. Maputo, Moçambique. 2017. .
    1. Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity development through the US President’s Malaria Initiative-supported antimalarial resistance monitoring in Africa Network. Merg Infect Dis. 2017;23:S53–S56.
    1. Lucchi NW, Narayanan J, Karell MA, Xayavong M, Kariuki S, DaSilva AJ, et al. Molecular diagnosis of malaria by photo-induced electron transfer fluorogenic primers: PET-PCR. PLoS ONE. 2013;8:e56677. doi: 10.1371/journal.pone.0056677.
    1. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467–1482. doi: 10.1093/oxfordjournals.molbev.a026247.
    1. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust algorithm for systematic classification of malaria late treatment failures as recrudescence or reinfection using microsatellite genotyping. Antimicrob Agents Chemother. 2015;59:6096–6100. doi: 10.1128/AAC.00072-15.
    1. Paczkowski M, Mwandama D, Marthey D, Luka M, Makuta G, Sande J, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi, 2014. Malar J. 2016;15:236. doi: 10.1186/s12936-016-1281-y.
    1. Plucinski MM, Dimbu PR, Macaia AP, Ferreira CM, Samutondo C, Quivinja J, et al. Efficacy of artemether-lumefantrine, dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015. Malar J. 2017;16:62. doi: 10.1186/s12936-017-1712-4.
    1. Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansané A, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J. 2009;8:200. doi: 10.1186/1475-2875-8-200.
    1. Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, et al. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol. 2005;59:298–301. doi: 10.1111/j.1365-2125.2004.02257.x.
    1. Staehli Hodel EM, Guidi M, Zanolari B, Mercier T, Duong S, Kabanywanyi AM, et al. Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J. 2013;12:235. doi: 10.1186/1475-2875-12-235.
    1. WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
    1. Abuaku B, Duah N, Quaye L, Quashie N, Malm K, Plange CB. Therapeutic efficacy of artesunate-amodiaquine and artemether-lumefantrine combinations in the treatment of uncomplicated malaria in two ecological zones in Ghana. Malar J. 2016;15:6. doi: 10.1186/s12936-015-1080-x.
    1. Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203. doi: 10.1186/1475-2875-8-203.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren